Longevity Health Holdings Inc. (Nasdaq: XAGE) has announced that it will continue its listing on the Nasdaq Stock Market as it moves forward with a merger with 20/20 BioLabs, Inc. The company received a favorable decision from the Nasdaq Hearings Panel, allowing it to proceed with the proposed merger, provided it meets Nasdaq's initial listing rules by September 2, 2025. As part of its strategy, Longevity Health Holdings has already filed the S-4 registration statement and completed a 1-for-30 reverse stock split to address listing requirements. The merger aims to enhance the company's focus on extending human longevity through regenerative bio-aesthetics, diagnostics, and nutrition.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.